Elicio Therapeutics, Inc. Retained Earnings
Elicio Therapeutics, Inc. (ELTX) had Retained Earnings of -$253.71 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-13
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$253.71M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$245.50M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$233.67M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$225.95M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$253.71M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | -$245.50M 10-Q · filed 2026-05-11 | |
| 2025-12-31 | -$233.67M 10-Q · filed 2026-08-13 | |
| 2025-09-30 | -$225.95M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | -$215.87M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | -$205.31M 10-Q · filed 2025-05-13 | |
| 2024-12-31 | -$194.10M 10-K · filed 2026-03-12 | |
| 2024-09-30 | -$180.10M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | -$161.26M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | -$154.03M 10-Q · filed 2024-05-15 | |
| 2023-12-31 | -$142.20M 10-K · filed 2025-03-31 | |
| 2023-09-30 | -$133.25M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | -$122.60M 10-Q · filed 2023-08-14 | |
| 2023-03-31 | -$258.48M 10-Q · filed 2023-05-10 | |
| 2022-12-31 | -$107.01M 10-K · filed 2024-03-29 | -$253.94M 10-K · filed 2023-03-17 |
| 2022-09-30 | -$247.50M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | -$238.51M 10-Q · filed 2022-08-15 | |
| 2022-03-31 | -$229.38M 10-Q · filed 2022-05-16 | |
| 2021-12-31 | -$215.13M 10-K · filed 2023-03-17 | |
| 2021-09-30 | -$230.03M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | -$214.32M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | -$197.25M 10-Q · filed 2021-05-17 | |
| 2020-12-31 | -$160.56M 10-K · filed 2022-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |